7 completed, 1 recruiting, 1 withdrawn. 4 Phase 1, 2 Phase 3, 1 Not applicable, 1 Phase 2.
By phase and status
Follow Endometriosis Related Pain: new trials by email Literature Review of Endometriosis Related Pain trials Research Report on Endometriosis Related Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital
Dronabinol Capsules, Placebo - Endometriosis, Endometriosis Related Pain | Phase 2 | Withdrawn | Baylor College of Medicine | | 2026-04-01 | 2026-03-13 |
Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates.
PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM, USUAL CARE - Endometriosis, Endometriosis Related Pain | Not applicable | Recruiting | University of Seville | 32 | 2025-05-01 | 2026-04-06 |
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 32 | 2020-08-12 | 2024-03-26 |
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
BAY1817080, [14C]BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 14 | 2020-08-05 | 2023-01-26 |
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
BAY1817080, Midazolam - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 37 | 2020-07-23 | 2023-01-20 |
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
BAY1817080, Matching Placebo - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 36 | 2020-02-15 | 2023-01-26 |
Bowel ENDOmetriosis; Evaluation of Diagnostics and Quality of Life
2D transvaginal ultrasound - Endometriosis Related Pain, Quality of Life | | Completed | Oslo University Hospital | 207 | 2018-12-10 | 2021-03-10 |
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo - Endometriosis Related Pain | Phase 3 | Completed | Myovant Sciences GmbH | 638 | 2017-12-07 | 2021-06-28 |
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo - Endometriosis Related Pain | Phase 3 | Completed | Myovant Sciences GmbH | 623 | 2017-11-01 | 2021-06-28 |
Narrower conditions
Endometriosis (4) · Pain (4) · Urinary Bladder, Overactive (4) · Dysmenorrhea (2) · Agnosia (1) · Chronic Disease (1) · Chronic Pain (1) · Intestinal Diseases (1) · Kidney Failure, Chronic (1) · Treatment Adherence and Compliance (1)
Broader conditions
Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Urogenital Diseases (8) · Neurologic Manifestations (5) · Genital Diseases (4) · Genital Diseases, Female (4) · Lower Urinary Tract Symptoms (4) · Male Urogenital Diseases (4) · Pathologic Processes (4) · Urinary Bladder Diseases (4) · Urologic Diseases (4) · Urological Manifestations (4) · Disease Attributes (2)
Interventions
Estradiol (2) · estradiol, norethindrone drug combination (2) · relugolix (2) · Dronabinol (1) · Midazolam (1)
Sponsors
Bayer (4) · Myovant Sciences GmbH (2) · Baylor College of Medicine (1) · Oslo University Hospital (1) · University of Seville (1)
Countries
United States (5) · Australia (2) · Czechia (2) · Poland (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Finland (1) · Georgia (1) · Hungary (1)
Top investigators
Christopher Verrico, PhD in Pharmacology (1) · Inmaculada Villa-del-Pino (1) · Manuel Rebollo-Salas (1) · Mee Kristine Aas-Eng, MD (1)
Results publications
PMID 35717987, PMID 37283994, PMID 37982388, PMID 31069056, PMID 38044419, PMID 38907175
NIH funding
2017 (2)